ioOligodendrocyte-like cells are highly characterised cells that resemble a pre-myelinating oligodendrocyte state. These cells enable the screening of compounds that modulate myelination, supporting drug development for neurodegenerative and demyelinating diseases, such as multiple sclerosis.
ioOligodendrocyte-like cells are precision reprogrammed from human iPSC using opti-ox™ technology, meaning scalability and consistency are built-in.
Upon thawing (day 1), cells are ready for experimentation and express the oligodendroglial lineage marker O4. By simply maintaining cells in a monolayer culture, cells rapidly mature and acquire a typical oligodendrocyte-like morphology with multiple branched processes. Cells start expressing oligodendrocyte markers, including MBP, PLP1, CNP and MAG.
Place your order
A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at email@example.com.
The opti-ox powered cells rapidly mature, transitioning into an oligodendrocyte-like morphology within 8 days
Time-lapse video capturing the rapid and homogeneous acquisition of an OPC-like morphology and maturation towards an oligodendrocyte-like morphology with multiple branched processes, upon thawing of cryopreserved cells. 8 day time course; scale bar: 500 μm.
Immunofluorescent staining of the cells at day 1 (upper panel) and day 8 (lower panel) post-revival. At day 1, the cells are positive for the oligodendrocyte-specific marker O4 (red), and the DAPI counterstain (blue). At day 8, ioOligodendrocyte-like cells show an increased complexity and are positive for O4 (red), the myelin basic protein (MBP) (green), and the DAPI counterstain (blue). 100X magnification; scale bar: 100 μm.
Cells show an oligodendrocyte-like morphology by day 8
Upon reprogramming, cells show rapid morphological changes, acquiring an OPC-like morphology by day 1 post-revival. By day 8, cells have matured and display an oligodendrocyte-like morphology. Brightfield images show day 1 and day 8 post-thawing; scale bar: 400 μm.
Key oligodendroglial genes are expressed by ioOligodendrocyte-like cells
Following reprogramming, the cells downregulate expression of the pluripotency gene OCT4, whilst demonstrating robust expression of relevant oligodendroglial markers, including PDGFRA, PLP1, MBP, CNP, MAG, and MYRF. Gene expression levels assessed by RT-qPCR, data expressed relative to the reference (housekeeping) gene, HMBS. Data represents day 1 and day 8 post-revival samples; n=2 technical replicates.
Whole transcriptome analysis demonstrates high lot-to-lot consistency of ioOligodendrocyte-like cells
Bulk RNA-sequencing analysis was performed on three different lots of manufactured product at day 1 and day 8 post revival. Principal component analysis (PCA) represents the variance in gene expression between the three different lots of ioOligodendrocyte-like cells. This analysis shows lots clustering very closely which demonstrates high consistency at each given timepoint. This lot-to-lot consistency in every vial gives scientists confidence in their experimental reproducibility. Colours represent the parental non-induced hiPSC cell line and the three lots of ioOligodendrocyte-like cells; shapes represent different timepoints.
Expression levels for specific genes of interest can be requested by contacting our team at firstname.lastname@example.org.
Cells arrive ready to plate
ioOligodendrocyte-like cells are delivered in a cryopreserved format and are programmed to rapidly mature upon revival in the recommended media. The protocol for the generation of these cells is a three-phase process: Induction, which is carried out at bit.bio (Phase 0), Stabilisation for 1 day (Phase 1), and Maturation from day 1 to day 8 (Phase 2). Phases 1 and 2 after revival of cells are carried out by the customer.
Human iPSC line
6, 12 and 24 well plates
Caucasian adult male (skin fibroblast)
Small >1 x 10⁶ viable cells
Sterility, protein expression (ICC) and gene expression (RT-qPCR)
opti-ox cellular reprogramming
Recommended seeding density
LN2 or -150°C
ioCells are for research use only
Screening of compounds that modulate myelination Phenotypic assays Target validation
*High-resolution Optical Genome Mapping (OGM) has identified a ∼16mb gain of the short arm of chromosome 12